AZN - ASTRAZENECA PLC
IEX Last Trade
66.485
-0.025 -0.038%
Share volume: 77,156
Last Updated: Thu 26 Dec 2024 08:30:01 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$66.51
-0.03
-0.04%
Fundamental analysis
50%
Profitability
34%
Dept financing
44%
Liquidity
48%
Performance
69%
Performance
5 Days
-0.50%
1 Month
-0.09%
3 Months
-15.20%
6 Months
-16.16%
1 Year
-0.30%
2 Year
-2.47%
Key data
Stock price
$66.48
DAY RANGE
$65.86 - $66.66
52 WEEK RANGE
$61.44 - $87.68
52 WEEK CHANGE
-$1.49
DIVIDEND
$0.50
EX-DIVIDEND DATE
08/09/2024
NEXT EARNINGS DATE
11/12/2024
Company detail
CEO: Pascal Soriot
Region: US
Website: astrazeneca.com
Employees: 83,500
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: astrazeneca.com
Employees: 83,500
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
AstraZeneca PLC focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. The company serves primary care and specialty care physicians through distributors in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia.
Recent news